Cumulative Incidence and Characteristics of Infections Requiring Treatment, Delay in Treatment Administration or Hospitalisation in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti BCMA or Anti GPRC5D Bispecific Antibodies

Background. Bispecific antibodies (BsAb) are a new effective treatment for relapsed/refractory multiple myeloma (RRMM). Although these immunotherapies are well tolerated, infectious complications emerged as a predominant issue, mainly with anti-BCMA BsAb. Recent guidelines were presented to prevent...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2023-11, Vol.142 (Supplement 1), p.1005-1005
Hauptverfasser:	Cellerin, Elise, Jourdes, Aurelie, Brousse, Xavier, Vallet, Nicolas, Cartau, Tom, Denis, Blandine, Harel, Stephanie, Jamard, Simon, Redor, Alexis, Cazaubiel, Titouan, Roland, Virginie, Caleteix, Carine, Charles, Morgane, Berger, Pierre, Escure, Guillaume, Collignon, Aude, Faure, Emmanuel, Cazelles, Clarisse, Lanternier, Fanny, de La Porte Des Vaux, Clementine, Frenzel, Laurent, Blot, Mathieu, Danion, Francois, Sonntag, Cécile, Touzeau, Cyrille, Pieragostini, Andrea, Ader, Florence, Karlin, Lionel, Macro, Margaret, martin-Blondel, Guillaume, Chalopin, Thomas, Perrot, Aurore
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!